RxDoctor Payments Data

Elizabeth Anoia-Loftus, MD

Urology · Huntingdon Valley, PANPI 1568419836

Payments from drug & device makers

$10,726in general payments, 2019–2025

Across 298 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Medtronic$1K
  • Dendreon Pharmaceuticals LLC$1K
  • Astellas Pharma US Inc$1K
  • Bluewind Medical$1K
  • AbbVie$738
  • plus $4K from 34 others

What the payments were for

  • Travel & lodging$2,09119%
  • Food & beverage$8,40478%
  • Education$2312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,726 in reported general payments places this provider in the 80th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$353,508
Medicare patients
1,023
Services billed
9,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron487$403,973
GemtesaVibegron311$216,262
Solifenacin Succinate266$10,067
Trimethoprim124$6,562
Silodosin67$4,874
Tamsulosin Hcl264$3,938
Estradiol58$3,315
Methenamine Hippurate26$2,029
Oxybutynin Chloride ErOxybutynin Chloride88$1,818
Finasteride118$1,692
Alfuzosin Hcl ErAlfuzosin Hcl46$1,352
Potassium Citrate ErPotassium Citrate16$1,206
Cefixime12$1,126
Dutasteride18$752
Oxybutynin Chloride31$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,060$403,973487 claims
Sumitomo Pharma America, Inc.Gemtesa$531$216,262311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 596 urology providers in Pennsylvania.

Other urology in Huntingdon Valley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →